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APPLICATION OF ULTRASOUND SHORTENED THE DECALCIFICATION DURATION
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Introduction: Calcium hydroxyapatite, Ca10(PO4)6(OH)2 accounts for 60% to 70% of
the bone tissue and contributes to the hardness of bone [1]. Decalcification is a
process to dissolution the hydroxyapatite complex in bone matrix to soften the
bone. After decalcification, the bone samples would be compatible with routine
paraffin histologic preparation. The traditional decalcification method requires
long incubation time and can lead to tissue swelling and hydrolysis of the bone ma-
trix [2]. Ultrasound (US) is believed to enhance the decalcification by a cavitation
mechanism [3]. We hypothesized that the application of US during bone decalcifi-
cation would accelerate the decalcification compare with the traditional decalci-
fication method without damaging bone tissue for histological assessments.
Methods: A human femur was obtained from Science Care (Arizona, USA) and was
sectioned into 5mm thick transverse sections. The bone slices (nZ6) were fixed in
4% phosphate buffered paraformaldehyde for 24 hours and were divided into two
groups: Ultrasound Decalcification group (US DeCal) and Normal Decalcification
group (Normal DeCal). For US DeCal, the bone sections were place in the US decal-
cifier (DeCa DX100, Pro-Cure Medical Technology Co. Ltd, Hong Kong, 50W at a fre-
quency of 40kHz) with 300mL of 0.5M EDTA solution. The temperature of the EDTA
solution was maintained at 30e45C. For the Normal DeCal, bone slices were
placed in a container with 300mL of 0.5M EDTA and maintained at 37C. All
EDTA solution was refreshed daily. The mineral content of the bone slices was
measured by micro-CT and Dual-energy X-ray absorptiometry (DXA) at different
time points. Calcium concentration of EDTA was measured by inductively coupled
plasma optical emission spectrometry (ICP-OES). After decalcification had been
completed, the samples were processed, embedded in paraffin, sectioned at
5mm, and stained with hematoxylin and eosin for analysis.
Results: For the US DeCal, the bone samples retained less than 7% of the mineral
content at Day 6 and they were completely decalcified by Day 8. For Normal DeCal,
the mineral content of these bone samples was 36.325.09% and 24.304.80% at
Day 6 and Day 8 respectively. In addition, Normal DeCal samples took over 50 Days
to complete decalcification. The concentration of calcium ions in the EDTA solu-
tion of the US DeCal group was 80% higher than the Normal DeCal (p<0.05). Histo-
logical analysis showed that there was no significant difference between the
sections of the two groups.
Discussion and Conclusion: Ultrasound decalcification accelerated the decalcifi-
cation process of human femoral bone slices compared with the traditional decal-
cification method. Our results suggested that decalcification by US shorten the
duration by six times compare with the normal decalcification. Others reported
that US shortened the decalcification process by 4e12 times depending on the
thickness of the sample and the type of tissues [2]. The application of ultrasound
technology would be suitable for the routine sample decalcification process for
bone histology in both basic and clinical research.
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Introduction:Osteosarcoma is themost common primarymalignant bone tumor and
has a high rate of systemic spread especially to the lungs. Primary metastasis is one
of the risk factors, and increases mortality rate. Podoplanin (PDPN/Aggrus), a
platelet aggregation-inducing type I transmembrane sialoglycoprotein, is involved
in tumor invasion and metastasis. Several studies have reported that osteosarcoma
expresses high levels of podoplanin. Moreover, podoplanin expression was reported
to be involved in poor prognosis of osteosarcoma patients. However, the association
between podoplanin expression and metastasis of osteosarcoma remains to be clar-
ified because of the lack of high-sensitive anti-podoplanin monoclonal antibodies
(mAbs), although many anti-podoplanin mAbs such as NZ-1 and D2-40 have been
established. In this study, we established a novel anti-podoplanin mAb, LpMab-7,
which possesses high sensitivity against podoplanin. Using LpMab-7, we investigated
podoplanin expression in primary and metastatic lesions of osteosarcomas.
Methods: Hybridoma production
BALB/c mice were immunized by i.p. injection of LN229/hPDPN cells. After several
additional immunizations with LN229/hPDPN cells, a booster injection was given
i.p. 2 days before spleen cells were harvested. The spleen cells were fused with
mouse myeloma P3U1 cells. The hybridomas were grown in RPMI medium with
hypoxanthine, aminopterin, and thymidine selection medium supplement. The
culture supernatants were screened using ELISA for binding to recombinant human
podoplanin purified from LN229/hPDPN cells.
Epitope mapping using ELISA, Western blot and flow cytometry
To determine the epitope of LpMab-7, ELISA was performed for synthetic peptides
of podoplanin. Several point mutants of podoplanin were produced and detected
using Western blotting and flow cytometry.
Immunohistochemistry (IHC) against osteosarcoma tissues
Tissue specimens from 16 osteosarcoma patients, who underwent surgery at
University Hospital of our institute, were used for IHC using LpMab-7, NZ-1, and D2-
40. Four pulmonary metastatic specimens were used for additional studies. The
study was approved by the institutional ethical committee. Informed consent for
obtaining samples and for subsequent data analyses was obtained from each
patient or the patient’s guardian.
Results: We first established a novel anti-podoplanin mAb, LpMab-7, by immu-
nizing mice with LN229/hPDPN. We next identified minimum epitope of LpMab-
7, and identified it as RIEDL, which corresponds to Arg79-Leu83 of human
120 Session: Otherspodoplanin using ELISA, Western-blot, and flow cytometry. Using IHC analysis,
LpMab-7 showed high reactivity against osteosarcoma tissues compared with NZ-
1 mAb. Furthermore, LpMab-7 detected podoplanin expressed in metastatic lesions
of osteosarcomas. Of interest, podoplanin expression at metastatic lesions was
higher compared with primarily lesions in 3 of 4 cases with lung metastasis.
Discussion: We investigated podoplanin expression by IHC using LpMab-7 mAb
against 16 osteosarcoma tissues, four of which have pulmonary metastatic lesions.
Although 3 of 4 metastatic lesions showed higher podoplanin expression than pri-
mary ones, more cases should be examined to conclude the association between
podoplanin expression and osteosarcoma metastasis. Because LpMab-7 has high
sensitivity against podoplanin, LpMab-7 mAb is expected to be useful for molecular
targeting therapy and a metastatic marker for osteosarcomas.
http://dx.doi.org/10.1016/j.jot.2016.06.144
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Introduction: The current standard of care in lower extremity long bone fracture
stabilization is closed intramedullary nailing (IMN). The surgical protocol associated
with this surgery is well defined. Yet, challenges arise that impede the surgicalwork-
flow and lead to frustration in the operating room. Specifically, two surgical steps of
entry point selection and reduction have been identified in the literature as themost
challenging steps. Both of these steps utilize 2D fluoroscopic imaging to guide 3D
alignment. Challenges arise when the alignment in one plane is lost while adjusting
the alignment in the perpendicular plane. This leads to unpredictable repetition of
activitieswhich can be time consuming and frustrating. The primary aimof this study
is to developan innovative surgical instrument to facilitate the entry point selection.
Methods: Design requirements were identified by shadowing three surgeons per-
forming eight IMN procedures in the operating room and conducting semi-struc-
tured interviews. Once a 3D model of the device was developed, a team,
consisting of an experienced staff surgeon, a junior orthopaedic surgeon, and a
mechanical engineer was consulted. Upon addressing the team comments, a po-
tential device design was finalized and prototyped. The prototype was shown to
the team to ensure the ease-of-use of the device as well as its functionality. How-
ever, multiple design improvements were made to optimize the ease-of-use of the
device. The prototype of the new design was manufactured and tested on a syn-
thetic bone with surrounding foam to simulate soft tissue. Three surgeons conduct-
ed the surgery under standard operating room conditions and provided feedback.
The above process allowed the inventors to finalize the device’s patent-pending
design and establish the device use protocol.
Results: The proposed design consists of a fixed frame and a rotatable multicannu-
lated arm to assist in guide wire insertion in femoral IMN. The device is initially
placed at the approximate IMN entry point location on the femoral head under
fluoroscopic image guidance. An anterior-posterior (AP) image is taken to align
the rotatable arm with the intramedullary canal of the femur. Once the 2D align-
ment is satisfactory, the device is temporarily fixed to the femoral head via two
pins. Based on the AP image a K-wire is placed into one of the three cannulated
entry point AP positions. A subsequent lateral (or oblique-lateral) image is then
taken to identify the correct 3D trajectory for accessing the intramedullary canal.
The device can then be adjusted within the selected plane to match the correct
trajectory via fixed rotation of the arm. The entry point can also be adjusted via
selection of an alternate lateral cannula. The K-wire is then advanced through
the cannulated guide into the intramedullary canal.
Conclusion: This simple device represents a novel surgical tool for use in IMN. In
contrast to the current entry point selection activity cycle (which may include
the acquisition of multiple AP and lateral images, patient repositioning and inaccu-
rate drilling), use of the device ensures maintenance of the 2D alignment obtained
in the AP plane while adjusting positioning in the perpendicular (lateral) plane.
http://dx.doi.org/10.1016/j.jot.2016.06.145
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Background: Potential biologic therapies have been developed for the prevention
of joint destruction in rheumatoid arthritis (RA) patients. However, 20e30 % of RA
patients using biologics including anti-TNF inhibitors are non-responders or only
minor improvement. Residual inflammation suggests a risk for progression of joint
destruction. Furthermore, recent evidence has strongly suggested that the onsetand progression of RA depend on many different factors including innate immune
sensors, such as Toll-like receptors (TLRs), participate in the induction of innate
inflammatory response, and also following adaptive and/or autoimmune responses
play an important role in RA inflammation.
Objectives: The aim of this study was to investigate the immunoinflammatory
cells, including Toll-like receptor (TLR)-equipped cells, in synovial tissue samples
from RA patients on anti-TNF inhibitors compared to patients with treatment of
conventional synthetic disease-modifying antirheumatic drug (csDMARD).
Methods: Immune-inflammatory cellswere evaluated in RA synovitis in patientswith
anti-TNF group [nZ20 (etanercept 14, infliximab 6)] or csDMARD group (nZ20) by
immunohistochemical and immunofluorescence study. Mean duration of affection
by RA of anti-TNF group and csDMARD-group was 8.3 years and 11.5 years, respec-
tively. Period of anti-TNF group was14 months. Mean CRP level of anti-TNF group
and csDMARD-group was 15 g/dl and 22 g/dl and that of DAS28-CRP score (4) of
anti-TNF group and csDMARD-group was 4.0 and 4.6 at collecting their samples,
respectively. CD3 (T cells), CD20 (B cells), CD68 (macropahges), S-100 (dendritic
cells:DC) and TLR1 to 9 immunoreactive cells were counted in at least five200 light
microscope fields in larger lymphoid infiltrates. The intensity of the inflammation
was estimated using the Krenn histopathological grading system (grade 0e3).
Results: The grading scores of synovitis was both 1.7 in each group and correlated
best with the T and B cells in the both groups (p<0.05). Interestingly, both T and B
cell counts were lower in the anti-TNF than in the csDMARD group (p<0.05). In
contrast, the C-reactive protein (CRP) and disease activity score DAS28-CRP did
not show clear-cut correlations with the inflammatory grade of the synovitis.
Similar numbers of cells immunoreactive for TLR-1 to TLR-9 were found in synovitis
in both groups.
Conclusion: Patients clinically responding to anti-TNF inhibitor might still have the
potential of moderate/severe local joint inflammation, composed in particular of
and possibly driven by the autoinflammatory TLR+ cells.
http://dx.doi.org/10.1016/j.jot.2016.06.146
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Background: It is well established that there is a strong genetic effect on bone
mass, bone loss and fracture risk; however, the vast majority of genetic variance
for osteoporosis-related phenotypes remains unexplained. Novel approaches are
needed to better identify the genetic underpinning of osteoporosis and to develop
an understanding of the physiological and pathological roles of genes identified in
this process.
Subjects and Methods:We utilised the Collaborative Cross (CC) Gene Mine mice to
identify genes associated with bone volume. We employed mCT to scan hindlimbs
of 940 CC mice across 56 strains incorporating multiple ages and genders where
available for each strain, and generated data on variables including BV/TV,
Tb.N, Tb.Sp, Tb.Th, SMI, DA and Ct.Th from reconstructed femur images using
CTAn software. Genomapping was then performed to identify candidate genes
responsible for bone volume. We also correlated the candidate genes with femoral
neck BMD in human cohorts.
Results: Dozens of candidate genes associated with these variables in mice were
identified based on our analyses. Based on linkage analyses of BV/TV, peak loci
were found at chromosome 13 in female mice and chromosome 3 in male mice,
respectively. The former locus harbours candidate genes like Epha5, Itga1, Pelo
and Itga2, and the latter harbours candidate genes like Snx27 and Tnxip. With com-
parison of young and old mice, peak loci were found at chromosome 11 and 17 in
female mice, suggesting potential genes like Fam83g and Rnf112; whereas peak
loci were found at chromosomes 2 and 12 in male mice, suggesting potential genes
such as Apob, Slc7a15, Laptm4a and Matn3. DA analyses in female mice showed
peak locus on chromosome 18, which harbours genes like Ska1, Myo5b, Lipg,
Epg5, Setbp1 and Nfatc.
Discussion and Conclusion: Among these candidate genes, five potential genes,
namely Txnip, Nfatc1, Setbp1, Apob and Itga1, have been reported to be associ-
ated with femoral neck BMD in human subjects. Nfatc1 has been extensively
explored in its role in the osteoclast fusion process. Txnip, which is linked to gluco-
corticoid-induced bone loss, is thought to be a strong candidate gene for bone
mass. Setbp1, which is closely related to Schinzel Giedion syndrome and atypical
CML, is hypothesised to produce a gain-of-function mutation which may result in
reduced PP2A and subsequently enhanced osteoblastogenesis. Itga1 is highly
expressed in osteoblasts and its loss has been identified to be correlated with
impaired fracture healing, accelerated knee osteoarthritis and reduced BMD in
humans. Apob is mainly responsible for carrying lipids. Mutations in this gene
